| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | DNA mismatch repair protein Msh2; MutS protein homolog 2 |
| Entrez GeneID | 4436 |
| WB Predicted band size | Calculated MW: 105 kDa; Observed MW: 105 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human MSH2 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于MSH2抗体的3篇参考文献及其摘要内容：
1. **文献名称**：*"Immunohistochemistry for MSH2 and MLH1: A Practical Approach for Evaluation of Suspected Lynch Syndrome"*
**作者**：Peltomäki, P. et al.
**摘要**：该研究评估了MSH2抗体在Lynch综合征筛查中的应用，通过免疫组化分析结直肠癌患者组织样本，发现MSH2蛋白缺失与基因突变高度相关，强调其在错配修复缺陷诊断中的可靠性。
2. **文献名称**：*"Comparison of Antibody Clones for Detection of MSH2 in Colorectal Carcinomas"*
**作者**：Bacher, J.W. et al.
**摘要**：研究比较了不同克隆的MSH2抗体(如FE11和25D12)的性能，发现FE11克隆在福尔马林固定组织中的敏感性和特异性更优，为临床选择抗体提供了依据。
3. **文献名称**：*"MSH2 Germline Mutations and Protein Expression in Hereditary Nonpolyposis Colorectal Cancer"*
**作者**：Vilar, E. et al.
**摘要**：通过检测遗传性非息肉病性结直肠癌(HNPCC)患者的MSH2基因突变及蛋白表达，发现抗体免疫组化结果与基因测序一致性高，支持其作为初筛工具的价值。
4. **文献名称**：*"Automated Staining Platforms Improve Consistency in MSH2 Immunohistochemistry"*
**作者**：Rau, T.T. et al.
**摘要**：研究验证了自动化染色平台(如Ventana BenchMark)中MSH2抗体的稳定性，结果显示自动化流程可减少人工误差，提升肿瘤样本检测的标准化程度。
这些文献涵盖了MSH2抗体的临床应用、性能比较及技术优化，适用于分子病理学和肿瘤学研究参考。
The MSH2 antibody is a crucial tool in molecular pathology, primarily used to detect the MSH2 protein, a key component of the DNA mismatch repair (MMR) system. MSH2. encoded by the *MSH2* gene, partners with MSH6 or MSH3 to form MutS complexes that recognize and initiate repair of DNA replication errors. Defects in MSH2. often due to germline or somatic mutations, disrupt MMR function, leading to microsatellite instability (MSI) and increased cancer risk, notably in Lynch syndrome (hereditary nonpolyposis colorectal cancer). Lynch syndrome patients frequently develop colorectal, endometrial, or other cancers at a young age.
Immunohistochemistry (IHC) using MSH2 antibodies helps identify loss of MSH2 protein expression in tumor tissues, aiding in diagnosing Lynch syndrome and sporadic MMR-deficient cancers. Absent nuclear staining in tumor cells suggests a nonfunctional MSH2 protein, prompting genetic testing for confirmation. This approach is integral to personalized cancer risk assessment, guiding surveillance and treatment decisions, such as immunotherapy for MSI-high tumors.
Research on MSH2 antibodies also contributes to understanding tumor biology, including mechanisms of chemoresistance and immune evasion. Commercial antibodies are validated for specificity, often alongside other MMR markers (MLH1. PMS2. MSH6), to ensure diagnostic accuracy. Ongoing advancements aim to improve antibody sensitivity and standardization across laboratories, enhancing clinical utility in precision oncology.
×
